News articles about Glaukos Corporation (NYSE:GKOS) have been trending somewhat positive on Monday, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Glaukos Corporation earned a news impact score of 0.22 on Accern’s scale. Accern also assigned media headlines about the medical instruments supplier an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:
- Glaukos Corporation (GKOS) Stock Rating Upgraded by Zacks Investment Research (americanbankingnews.com)
- Wimbledon 2017: Venus Williams looking to strike for old brigade (cromaplus.net)
- Piedmont Office Realty Trust, Inc. (NYSE:PDM) Valuation According To Analysts (nolopodrasdejardever.com)
- Needle Action Activity Spotted in Glaukos Corp (GKOS) – Financial News Review (finnewsreview.com)
- Stock within investor Spotlight: Glaukos Corporation (GKOS) – Morning Times (wallstreetmorning.com)
Several research analysts recently weighed in on GKOS shares. BMO Capital Markets restated a “buy” rating and set a $54.00 price target on shares of Glaukos Corporation in a report on Tuesday, April 11th. Zacks Investment Research upgraded shares of Glaukos Corporation from a “hold” rating to a “buy” rating and set a $45.00 price target on the stock in a report on Friday. BidaskClub upgraded shares of Glaukos Corporation from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. TheStreet cut shares of Glaukos Corporation from a “c” rating to a “d+” rating in a report on Wednesday, May 3rd. Finally, Stephens upgraded shares of Glaukos Corporation from an “equal weight” rating to an “overweight” rating in a report on Monday, May 8th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $48.50.
Shares of Glaukos Corporation (GKOS) opened at 39.78 on Monday. The firm has a 50-day moving average of $40.47 and a 200 day moving average of $42.42. Glaukos Corporation has a 12 month low of $28.26 and a 12 month high of $52.49. The company has a market cap of $1.36 billion, a price-to-earnings ratio of 361.64 and a beta of 1.33.
ILLEGAL ACTIVITY NOTICE: “Glaukos Corporation (NYSE:GKOS) Receiving Somewhat Positive News Coverage, Study Shows” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.com-unik.info/2017/07/17/glaukos-corporation-nysegkos-receiving-somewhat-positive-news-coverage-study-shows.html.
Glaukos Corporation Company Profile
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
What are top analysts saying about Glaukos Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Glaukos Corporation and related companies.